Boston Therapeutics Corporate Update
(firmenpresse) - MANCHESTER, NH -- (Marketwire) -- 04/02/12 -- Boston Therapeutics Inc. (OTCBB: BTHE), a developer of diabetes therapeutics, reviews the series of events that have led to the availability of its lead product SUGARDOWN®, and its status as a publicly traded company.
Boston Therapeutics submitted SUGARDOWN® structure and function claims to the US Food and Drug Administration as a novel non-systemic chewable dietary supplement that supports glycemic control and digestive health.
Following the submission to the US Food and Drug Administration, Boston Therapeutics licensed exclusive rights to commercialize SUGARDOWN® for blood sugar management in China to Advance Pharmaceutical Co. Ltd.
Last year Boston Therapeutics also completed a human clinical study with SUGARDOWN® at University of Sydney, Australia and initiated a Phase 2 Clinical Trial of PAZ320 in Type 2 Diabetes at Dartmouth-Hitchcock Medical Center, New Hampshire.
A few months ago, Boston Therapeutics received its first purchase order for sales of SUGARDOWN® in Italy and announced clinical study safety results with SUGARDOWN® at University of Sydney in Australia.
Boston Therapeutics recently received regulatory clearance to be listed on the OTC Bulletin Board and was quoted under the ticker BTHE.OB
Boston Therapeutics, headquartered in Manchester, NH, is a leader in the field of glyco-pathology, a specialized field involving understanding the importance of carbohydrates in biochemistry and progression of diseases. The Company's initial product pipeline is focused on developing and commercializing therapeutic molecules for diabetes: PAZ320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose excursion; SUGARDOWN®, a non-systemic chewable complex carbohydrate dietary supplement designed to moderate post-meal blood glucose; and IPOXYN™, a systemic, injectable complex carbohydrate-based oxygen therapeutic for limb ischemia.
Additional information is available at and
For more information about Boston Therapeutics, its lead OTC product, SUGARDOWN®, PAZ320, or Ipoxyn™, please visit and
Company Contact:
Ken Tassey
President, COO
978-886-0421
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 02.04.2012 - 13:57 Uhr
Sprache: Deutsch
News-ID 1099181
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
MANCHESTER, NH
Phone:
Kategorie:
Health & Nutrition
Anmerkungen:
Diese Pressemitteilung wurde bisher 121 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Boston Therapeutics Corporate Update
"
steht unter der journalistisch-redaktionellen Verantwortung von
Boston Therapeutics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
